CURX
What one share of Curanex Pharmaceuticals holds
Pharmaceutical Preparations
If the Phase I trial is completed with positive results, we intend to proceed with a Phase II trial for ulcerative colitis as our lead indication.
Curanex Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.38 |
|---|---|
| Cash and investments | $0.10 |
| Book value | $0.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.03 | — | −$0.04 | — | $0.02 |
| 2025 | — | −$0.17 | — | −$0.41 | — | $0.40 |